Summary & Overview
HCPCS J1640: Hemin Injection, 1 mg
HCPCS Level II code J1640 designates the injectable administration of hemin, reported per 1 mg unit. Hemin is an acute and maintenance therapy for certain porphyrias and other heme-related deficiencies; accurate coding supports correct billing, utilization tracking, and coverage determinations for a high-cost injectable medication. Nationally, clear use of HCPCS Level II code J1640 impacts reimbursement processing, prior authorization workflows, and inventory management across settings that administer specialty infusions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for hemin injections, typical sites of service where claims are generated, and the payer landscape addressed by common coverage and billing practices. The publication summarizes benchmark considerations, relevant policy updates that affect billing and prior authorization, and guidance on standard claim reporting elements associated with HCPCS Level II code J1640.
This resource is intended for revenue cycle managers, clinicians involved in infusion services, and coding professionals seeking a national perspective on the use and administrative handling of HCPCS Level II code J1640 for hemin injection services.
Billing Code Overview
HCPCS Level II code J1640 describes the administration of hemin as an injection, quantified per 1 mg. The service represents a physician- or facility-administered therapeutic infusion or injection intended to deliver the active drug product. Typical service type: injectable medication administration. Typical site of service: hospital outpatient department, infusion center, clinic, or physician office.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute porphyria or hereditary hemochromatosis complications requiring parenteral hemin therapy. The patient presents to an outpatient infusion center or hospital inpatient unit with worsening symptoms such as severe abdominal pain, neurologic deficits, and dark urine consistent with an acute porphyric attack. The clinical workflow includes triage and assessment by a physician or advanced practice provider, verification of the diagnosis and indication for hemin, allergy and drug reconciliation, consent and baseline vital signs, venous access placement or verification of existing peripheral or central line, pharmacy preparation of J1640 (hemin) in the correct concentration and volume, administration via slow intravenous infusion per institutional protocol, monitoring for infusion reactions and phlebitis, documentation of lot number and units administered, and post-infusion observation before discharge or transfer to inpatient care. Typical sites of service are hospital inpatient, hospital outpatient infusion center, or freestanding infusion center depending on acuity and payor coverage. Common patient scenario modifiers may include JW for discarded drug, QX/QY/QK when applicable for provider ownership or supervision arrangements, and AS for ambulatory surgical center billing when applicable, though hemin is most frequently billed in infusion or inpatient settings.
Coding Specifications
| Modifier |
|---|